Medical Management of Castleman's Disease

Classification and Diagnosis

The American College of Oncology recommends classifying Castleman's disease into unicentric and multicentric forms based on lymph node involvement, with multicentric disease further divided into HHV-8-associated and idiopathic forms 1
Laboratory evaluation for Castleman's disease should include complete blood count with differential, inflammatory markers, and HHV-8 testing, as recommended by the American College of Oncology 1
HIV testing is recommended for patients with Castleman's disease, as stated by the American Society of Transplantation 2

The American College of Oncology recommends rituximab monotherapy as first-line treatment for HHV-8-associated multicentric Castleman disease, with the option to add etoposide for severe cases or cytotoxic chemotherapy for patients with Kaposi sarcoma 1
Antiretroviral therapy should always be administered in HIV-positive patients with HHV-8-associated multicentric Castleman disease, as recommended by the American College of Oncology 1

The American College of Oncology does not provide specific recommendations for the treatment of idiopathic multicentric Castleman disease, but other sources suggest considering triple therapy with corticosteroids, rituximab, and cyclophosphamide for severe inflammation or inadequate response to IL-6 blockade 3

Clinical follow-up every 3-6 months is recommended for patients with Castleman's disease, with monitoring for disease relapse, development of non-Hodgkin lymphoma, and reactivation or progression of concomitant Kaposi sarcoma, as stated by the American College of Oncology 1

Rituximab treatment reduces the incidence of non-Hodgkin lymphoma in patients with Castleman's disease, but the risk remains high, as reported by the American College of Oncology 1

Splenectomy may be considered in cases with severe refractory anemia and thrombocytopenia, as recommended by the American College of Oncology 1
POEMS syndrome may be associated with Castleman's disease and requires specific diagnostic workup, as stated by the American Academy of Neurology 4

The American Society of Hematology recommends interferon-based therapies and anakinra for pediatric Castleman's disease, with success reported in case reports 5
Corticosteroid monotherapy has been successful in isolated cases of pediatric Castleman's disease 5
Direct implementation of Langerhans cell histiocytosis protocols has been unsuccessful in pediatric Castleman's disease 5

The American Society of Hematology suggests treatment should be continued indefinitely if tolerated, with 68% 5-year survival reported with modern therapies, particularly interferon-based treatment 5